DiaMedica Therapeutics Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $8.38
- 52-Week Range
- $5.25 – $11.00
- Market Cap
- $463.49M
- P/E (TTM)
- —
- EPS (TTM)
- -0.77
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 16.18
- PEG Ratio
- —
- Return on Equity
- -100.23%
- Return on Assets
- -56.08%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 4.76
- Debt/Equity
- 0.01
- Total Debt
- $157.00K
- Free Cash Flow
- $-18.95M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $428.75M
Market Snapshot
About
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for neurological and kidney diseases. The company's lead product candidate, DM199, is a recombinant human tissue kallikrein-1 protein being studied for acute ischemic stroke and chronic kidney disease. DiaMedica focuses on leveraging the therapeutic properties of the kallikrein-kinin system. The company conducts clinical trials and preclinical research while seeking regulatory approval pathways for its drug candidates.